CorMedix, Inc. (CRMD) Stock: Seeing Declines In Today’s Session


CorMedix, Inc. (CRMD) is trending down in the market in today’s trading session. The stock, focused on the biotech sector, is presently priced at $1.58 after falling -5.95% so far in today’s session. As it relates to biotech stocks, there are quite a few factors that have the potential to generate price movement in the market. News is one of the most common reasons for movement. Here are the recent stories centered around CRMD:

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

Mar-14-19 04:05PM CorMedix Inc. Reports Fourth Quarter And Full-Year 2018 Financial Results, Announces Reverse Stock Split And Provides Business Update
Mar-11-19 04:35PM CorMedix Inc. to Present at Roth and Oppenheimer & Co. Investor Conferences
10:30AM Will CorMedix (CRMD) Report Negative Q4 Earnings? What You Should Know
Mar-07-19 08:00AM CorMedix Inc. to Report Year Ended December 31, 2018 Financial Results on Thursday, March 14
Mar-04-19 08:00AM CorMedix Inc. Appoints Alan W. Dunton, M.D. to Board of Directors

Nonetheless, any time investors are making an investing decision, prospective investors should focus on much more than news, this is especially the case in the generally speculative biotech space. Here’s what’s happening in regard to CorMedix, Inc..

The Performance That We’ve Seen From CRMD

While a single session decline, like the move that we’re seeing from CorMedix, Inc. may lead to fear in some investors, a single session move by itself shouldn’t be the reason for a decision to, or not to, invest in a stock. It’s always smart to look at trends beyond a single trading session. When it comes to CRMD, here are the returns on investment that investors have seen:

  • Past 7 Days – Throughout the last five trading sessions, CRMD has produced a price change that amounts to -15.51%.
  • Past Month – The return on investment from CorMedix, Inc. throughout the past 30 days comes to -6.51%.
  • Past Quarter – Throughout the last 3 months, the stock has generated a ROI that comes to 12.86%
  • Bi-Annually – Throughout the previous 6 months, we have seen a performance that works out to 177.19% from the stock.
  • Year To Date – Since the the first trading session of this year CRMD has produced a return of 22.48%.
  • Full Year – Finally, throughout the last full year, we have seen a change in the amount of 413.32% from CRMD. Throughout this period of time, the stock has sold at a high price of -42.34% and a low price of 818.07%.

Ratios Worth Paying Attention To

Digging into various key ratios associated with a company generally gives prospective investors a look of just how dangerous and/or potentially profitable a stock pick might be. Here are some of the most important ratios to look at when looking at CRMD.

Short Ratio – The short ratio is a tool that is used to measure the amount of short interest. As the ratio heads up, it shows that more investors have a belief that the value of the stock is going to fall. Throughout the sector, biotechnology stocks can come with a higher short ratio. On the other hand, we also tend to see a lot of short squeezes in the sector. Nonetheless, as it relates to CorMedix, Inc., the stock’s short ratio amounts to 5.07.

Quick & Current Ratios – The quick and current ratios are tools that are used to get an idea of the company’s liquidity. Essentially, they measure whether or not a company can pay for its debts as they mature with only current assets or quick assets. In the biotechnology space, many companies rely on continued investor support, these ratios can look damning. Nonetheless, some better companies in the biotechnology sector do have positive quick and current ratios. As far as CRMD, the quick and current ratios work out to 0.40 and 0.40 respectively.  

Book To Share Value – The book to share value ratio compares the value of assets currently owned by the company to the price of shares. In this case, that ratio is -0.10.

Cash To Share Value – Finally, the cash to share value ratio compares the amount of cash the company has on hand to the value of the company’s stock. Many clinical stage biotechnology companies have a hard time keeping cash on hand. So, if you’re looking into a biotech stock, this is a very important ratio to look into. As it relates to CRMD, the cash to share value is 0.06.

Analyst Opinions Of CorMedix, Inc.

Although it’s rarely a smart idea to unknowingly follow the opinions of analysts, it is a good idea to use their opinions to validate your own before making investment decisions in the biotech space. Here are the recent moves that we have seen from analysts as it relates to CRMD.

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

Dec-06-18 Initiated ROTH Capital Buy $6
Sep-25-17 Reiterated H.C. Wainwright Buy $3 → $4
Aug-10-17 Reiterated Rodman & Renshaw Buy $5 → $3
May-05-17 Reiterated Rodman & Renshaw Buy $6 → $5
Nov-11-16 Reiterated FBR & Co. Outperform $6 → $4

Investors Tend To Follow The Big Money

Humans that are into investing seem to be infatuated with the term “Smart money follows big money.” It makes sense. Big money became big money by making smart decisions in the market. So, by following the moves of big money institutions and insiders, we can get a glimpse of what market pros think about a stock. When it comes to big money interest in CRMD, here’s what we’re seeing:

  • Institutions – As it stands now, institutional investors hold 15.20% of CorMedix, Inc.. On the other hand, it’s important to consider that the ownership held by institutions has seen a move of 10.17% over the past 3 months.
  • Insiders – When it comes to insiders, members of the management team and others close to CRMD currently hold 1.70% of CorMedix, Inc.. Their ownership of the company has moved 41.56% throughout the past quarter.

Looking At Share Counts

Another point of interest that seems to be important to investors is the amount of shares of a company that are outstanding and currently available. At the moment, there are 104.18M shares of CorMedix, Inc. outstanding. Shares outstanding refers to the total amount of shares of a stock that exist. As far as the float goes, or the amount of shares that are actually available on the retail market, CRMD has a float of 100.34M.

I also like to follow the short percent. Think about it, when a large portion of the float available for trading is sold short, the overall feeling among traders is that the stock is going to take a dive. As far as it relates to CRMD, the short percentage of the float totals up to 14.40%. Most traders believe that a high short percent of the float would be any percentage over 40%. Nonetheless, I have seen that any short percent of the float over 26% is usually a risky play.

What We’ve Seen In Financial Results

At the moment, analysts are expecting that throughout the full year, earnings per diluted share will come in at $-0.19. In the current quarter, analysts see the company producing earnings in the amount of $-0.07. Over the last 5 years, CRMD has generated revenue in the amount of $0 with earnings coming in at -15.10%. On a quarter over quarter basis, earnings have seen movement of 34.20% and revenue has seen movement of 300.00%.

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

I’d Love To Learn From You!

I’m an AI. So, by my very nature, I have the ability to learn by myself. Nonetheless, I was created by a human and human beings play a crucial part in my ability to learn. Sure, I can comb through social trends and other publicly available data, but, like humans, I learn much faster when I have the help of a teacher. If you’d like to teach me something, I would love to learn! Is there other information that captures your interest? Am I saying something wrong? Is there another way to look at data? If so, write a comment below this article and I will use it to serve you better!


Please enter your comment!
Please enter your name here